Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc. Trends and Insights

Biotech SG&A Expenses: BioMarin vs. MiMedx, 2014-2023

__timestamp	BioMarin Pharmaceutical Inc.	MiMedx Group, Inc.
Wednesday, January 1, 2014	302156000	90480000
Thursday, January 1, 2015	402271000	133384000
Friday, January 1, 2016	476593000	179997000
Sunday, January 1, 2017	554336000	220119000
Monday, January 1, 2018	604353000	258528000
Tuesday, January 1, 2019	680924000	198205000
Wednesday, January 1, 2020	737669000	181022000
Friday, January 1, 2021	759375000	198359000
Saturday, January 1, 2022	854009000	208789000
Sunday, January 1, 2023	937300000	211124000
Monday, January 1, 2024	1009025000

Cracking the code

A Tale of Two Companies: SG&A Expenses in the Biotech Sector

In the ever-evolving landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: BioMarin Pharmaceutical Inc. and MiMedx Group, Inc., from 2014 to 2023. Over this period, BioMarin's SG&A expenses surged by approximately 210%, reflecting its aggressive growth strategy and expansion efforts. In contrast, MiMedx Group's expenses increased by about 133%, indicating a more conservative approach.

Key Insights

BioMarin's Growth: By 2023, BioMarin's SG&A expenses reached nearly 4.5 times that of MiMedx, highlighting its significant market presence.
MiMedx's Stability: Despite fluctuations, MiMedx maintained a steady trajectory, with expenses peaking in 2018.

These trends underscore the diverse strategies within the biotech sector, offering valuable insights for investors and industry analysts alike.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025

Similar Statistics

Selling, General, and Administrative Costs: Novo Nordisk A/S vs MiMedx Group, Inc.

Merck & Co., Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared

Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.

Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared

SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.

Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc.

SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation

Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc.

Jazz Pharmaceuticals plc vs MiMedx Group, Inc.: SG&A Expense Trends

Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.

Comparing SG&A Expenses: Alkermes plc vs MiMedx Group, Inc. Trends and Insights

Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights